Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data
dc.contributor.author | Díaz, Natalia A | |
dc.contributor.author | de Miguel, Rosa | |
dc.contributor.author | Agüero, Fernando | |
dc.contributor.author | Sued, Omar | |
dc.contributor.author | Arribas, José R | |
dc.contributor.author | Ambriosioni, Juan | |
dc.contributor.author | Hospital Clinic COVID-19 in HIV Investigators | |
dc.date.accessioned | 2024-05-23T23:49:02Z | |
dc.date.available | 2024-05-23T23:49:02Z | |
dc.date.issued | 2021-08 | |
dc.description | Fil: Díaz NA. Infectious Diseases Service, Hospital Cuenca Alta, Cañuelas; Argentina | es_ES |
dc.description.abstract | The HIV pandemic has led to close to 40 million people living with HIV (PLWH) worldwide. To date, SARS-CoV2 has affected > 220 million people, and unprecedented global efforts have resulted in almost 6000 million doses of SARS-CoV2 vaccines being administered. Although several specific COVID-19 antiviral and anti-inflammatory treatments and SARS-CoV2 vaccines have been approved, the data available to support their use in specific populations such as PLWH remain limited. PLWH includes a range of individuals from practically unaffected immunity to severely immunocompromised individuals, and preventive and therapeutic interventions should be tailored for these subgroups . However, in most randomized clinical trials regarding antivirals, immunomodulators and vaccines for COVID-19, PLWH have been excluded or only enrolled in small numbers leading to a paucity of data. We briefly discuss the current evidence for prevention and treatment of COVID-19 in PLWH and identify key areas where more information is required. | es_ES |
dc.format | application/pdf | es_ES |
dc.identifier.doi | https://doi.org/10.1007/s40121-021-00547-y | |
dc.identifier.uri | https://repositorio.huesped.org.ar/handle/123456789/1301 | |
dc.language | ENG | es_ES |
dc.provenance | Published | es_ES |
dc.relation.ispartofseries | Infectious Diseases and Therapy;2022 Feb;11(1):1-13. | |
dc.rights | openAccess | es_ES |
dc.subject | COVID-19 | es_ES |
dc.subject | VIH | es_ES |
dc.subject | Infecciones por VIH | es_ES |
dc.subject | SARS-CoV-2 | es_ES |
dc.subject | Vacunas contra la COVID-19 | es_ES |
dc.subject | Terapéutica | es_ES |
dc.title | Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data | es_ES |
dc.type | Articulo | es_ES |